INTRODUCTION: Chronic systemic corticosteroid (CS) therapy is associated with an increased risk of mortality in patients with many chronic diseases. However, it has not been elucidated whether chronic systemic CS therapy is associated with increased mortality in patients with asthma. The aim of this study was to determine the effects of chronic systemic CS therapy on long-term mortality in adult patients with asthma. METHODS: A population-based matched cohort study of males and females aged ≥18 years with asthma was performed using the Korean National Health Insurance Service database from 2005 to 2015. Hazard ratio (HR) with 95% confidence interval for all-cause mortality among patients in the CS-dependent cohort (CS use ≥6 months during baseline period) relative to those in the CS-independent cohort (CS use <6 months during baseline period) was evaluated. RESULTS: The baseline cohort included 466 941 patients with asthma, of whom 8334 were CS-dependent and 458 607 were CS-independent. After 1:1 matching, 8334 subjects with CS-independent asthma were identified. The HR of mortality associated with CS-dependent asthma relative to CS-independent asthma was 2.17 (95% CI 2.04-2.31). In patients receiving low-dose CS, the HR was 1.84 (95% CI 1.69-2.00); in patients receiving high-dose CS, the HR was 2.56 (95% CI 2.35-2.80). CONCLUSIONS: In this real-world, clinical practice, observational study, chronic use of systemic CS was associated with increased risk of mortality in patients with asthma, with a significant dose-response relationship between systemic CS use and long-term mortality.
INTRODUCTION: Chronic systemic corticosteroid (CS) therapy is associated with an increased risk of mortality in patients with many chronic diseases. However, it has not been elucidated whether chronic systemic CS therapy is associated with increased mortality in patients with asthma. The aim of this study was to determine the effects of chronic systemic CS therapy on long-term mortality in adult patients with asthma. METHODS: A population-based matched cohort study of males and females aged ≥18 years with asthma was performed using the Korean National Health Insurance Service database from 2005 to 2015. Hazard ratio (HR) with 95% confidence interval for all-cause mortality among patients in the CS-dependent cohort (CS use ≥6 months during baseline period) relative to those in the CS-independent cohort (CS use <6 months during baseline period) was evaluated. RESULTS: The baseline cohort included 466 941 patients with asthma, of whom 8334 were CS-dependent and 458 607 were CS-independent. After 1:1 matching, 8334 subjects with CS-independent asthma were identified. The HR of mortality associated with CS-dependent asthma relative to CS-independent asthma was 2.17 (95% CI 2.04-2.31). In patients receiving low-dose CS, the HR was 1.84 (95% CI 1.69-2.00); in patients receiving high-dose CS, the HR was 2.56 (95% CI 2.35-2.80). CONCLUSIONS: In this real-world, clinical practice, observational study, chronic use of systemic CS was associated with increased risk of mortality in patients with asthma, with a significant dose-response relationship between systemic CS use and long-term mortality.
Authors: Ji-Hyang Lee; Hyo-Jung Kim; Chan Sun Park; So Young Park; So-Young Park; Hyun Lee; Sang-Heon Kim; You Sook Cho Journal: Allergy Asthma Immunol Res Date: 2022-07 Impact factor: 5.096
Authors: Hayoung Choi; Sang Hyuk Kim; Kyungdo Han; Tai Sun Park; Dong Won Park; Ji-Yong Moon; Sang-Heon Kim; Tae-Hyung Kim; Jang Won Sohn; Ho Joo Yoon; Hyun Lee Journal: Respir Res Date: 2022-10-18
Authors: Francesco Menzella; Elena Bargagli; Maria Aliani; Pietro Bracciale; Luisa Brussino; Maria Filomena Caiaffa; Cristiano Caruso; Stefano Centanni; Maria D'Amato; Stefano Del Giacco; Fausto De Michele; Fabiano Di Marco; Elide Anna Pastorello; Girolamo Pelaia; Paola Rogliani; Micaela Romagnoli; Pietro Schino; Gianenrico Senna; Alessandra Vultaggio; Lucia Simoni; Alessandra Ori; Silvia Boarino; Gianfranco Vitiello; Elena Altieri; Giorgio Walter Canonica Journal: Respir Res Date: 2022-02-19
Authors: Byung Keun Kim; So Young Park; Ga Young Ban; Mi Ae Kim; Ji Hyang Lee; Jin An; Ji Su Shim; Youngsoo Lee; Ha Kyeong Won; Hwa Young Lee; Kyoung Hee Sohn; Sung Yoon Kang; So Young Park; Hyun Lee; Min Hye Kim; Jae Woo Kwon; Sun Young Yoon; Jae Hyun Lee; Chin Kook Rhee; Ji Yong Moon; Taehoon Lee; So Ri Kim; Jong Sook Park; Sang Heon Kim; Heung Woo Park; Jae Won Jeong; Sang Hoon Kim; Young Il Koh; Yeon Mok Oh; An Soo Jang; Kwang Ha Yoo; You Sook Cho Journal: Allergy Asthma Immunol Res Date: 2020-11 Impact factor: 5.764
Authors: Katarzyna Niespodziana; Kristina Borochova; Petra Pazderova; Thomas Schlederer; Natalia Astafyeva; Tatiana Baranovskaya; Mohamed-Ridha Barbouche; Evgeny Beltyukov; Angelika Berger; Elena Borzova; Jean Bousquet; Roxana S Bumbacea; Snezhana Bychkovskaya; Luis Caraballo; Kian Fan Chung; Adnan Custovic; Guillermo Docena; Thomas Eiwegger; Irina Evsegneeva; Alexander Emelyanov; Peter Errhalt; Rustem Fassakhov; Rezeda Fayzullina; Elena Fedenko; Daria Fomina; Zhongshan Gao; Pedro Giavina-Bianchi; Maia Gotua; Susanne Greber-Platzer; Gunilla Hedlin; Natalia Ilina; Zhanat Ispayeva; Marco Idzko; Sebastian L Johnston; Ömer Kalayci; Alexander Karaulov; Antonina Karsonova; Musa Khaitov; Elena Kovzel; Marek L Kowalski; Dmitry Kudlay; Michael Levin; Svetlana Makarova; Paolo Maria Matricardi; Kari C Nadeau; Leyla Namazova-Baranova; Olga Naumova; Oleksandr Nazarenko; Paul M O'Byrne; Faith Osier; Alexander N Pampura; Carmen Panaitescu; Nikolaos G Papadopoulos; Hae-Sim Park; Ruby Pawankar; Wolfgang Pohl; Harald Renz; Ksenja Riabova; Vanitha Sampath; Bülent E Sekerel; Elopy Sibanda; Valérie Siroux; Ludmila P Sizyakina; Jin-Lyu Sun; Zsolt Szepfalusi; Tetiana Umanets; Hugo P S Van Bever; Marianne van Hage; Margarita Vasileva; Erika von Mutius; Jiu-Yao Wang; Gary W K Wong; Sergii Zaikov; Mihaela Zidarn; Rudolf Valenta Journal: J Allergy Clin Immunol Date: 2020-02-18 Impact factor: 14.290